Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'
With news of Merck’s flagship BACE drug going down to complete failure in a late-stage Alzheimer’s study still reverberating through a dispirited R&D field, Biogen is now pitching in to make things even worse.
Shares of Biogen $BIIB tumbled about 7% Wednesday afternoon after their CMO Al Sandrock shocked some attendees at the Leerink Healthcare Conference by saying that the company had decided to add 510 patients to its pivotal study for the closely-watched drug aducanumab.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters